Clinical efficacy of trimethoprim-sulfamethoxazole treatment for pediatric pertussis in macrolide-resistant endemic regions: A retrospective cohort study
SXT effectively alleviates clinical symptoms of pertussis in children in high MRBP prevalence regions. Nucleic acid negative conversion predicts clinical remission. An extended SXT course (10-14 days) demonstrates superior efficacy to a shorter course (5-7 days). No serious adverse events were observed; skin lesions were the most common side effect.
Authors
- Wenjuan Zhao
- Zengguo Wang
- Juan Yuan
- Bin Xue
- Fangzhi He
- Shuyue Tang
- Xinxin Zhu
- Yarong Yang
- Jun Wang
- Yi Zhang
Institutions
- Xi’an Children’s Hospital (CN)
- Shaanxi University of Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jgar.2026.01.011
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 0.00